Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer

3 Apr 2018

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to BRCA gene mutations in cancer
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 29635390
DOI: 10.1093/annonc/mdy099

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 3 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancerPMID 29635390Read ↗

RAD51 as a functional biomarker for homologous recombination deficiency in cancer: a promising addition to the HRD toolbox?Semantic proximity Read ↗

Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?Semantic proximity Read ↗

Preclinical In Vivo Validation of the RAD51 Test for Identification of Homologous Recombination-Deficient Tumors and Patient StratificationSemantic proximity Read ↗

RAD51 and PALB2 in precision oncology: Clinical implications for HRD associated breast and ovarian cancers (Review)Semantic proximity Read ↗

Clinical and biological significance of RAD51 expression in breast cancer: a key DNA damage response proteinSemantic proximity Read ↗

Regulation and pharmacological targeting of RAD51 in cancerSemantic proximity Read ↗

RAD51 as a potential surrogate marker for DNA repair capacity in solid malignanciesSemantic proximity Read ↗

A RAD51 assay feasible in routine tumor samples calls PARP inhibitor response beyond BRCA mutationSemantic proximity Read ↗

Targeting RAD51-Mediated Homologous Recombination as a Treatment for Advanced Solid and Hematologic Malignancies: Opportunities and Challenges AheadSemantic proximity Read ↗

Functional and mutational landscapes of BRCA1 for homology-directed repair and therapy resistanceSemantic proximity Read ↗

Functional <i>Ex Vivo</i> Assay to Select Homologous Recombination–Deficient Breast Tumors for PARP Inhibitor TreatmentSemantic proximity Read ↗

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.